AU2008260483A1 - High temperature stable peptide formulation - Google Patents

High temperature stable peptide formulation Download PDF

Info

Publication number
AU2008260483A1
AU2008260483A1 AU2008260483A AU2008260483A AU2008260483A1 AU 2008260483 A1 AU2008260483 A1 AU 2008260483A1 AU 2008260483 A AU2008260483 A AU 2008260483A AU 2008260483 A AU2008260483 A AU 2008260483A AU 2008260483 A1 AU2008260483 A1 AU 2008260483A1
Authority
AU
Australia
Prior art keywords
peptide
formulation
lyophilized
seq
reconstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2008260483A
Other languages
English (en)
Inventor
Russell Wayne Blacher
Byeong Chang
Dennis Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Big Bear Bio Inc
Original Assignee
Big Bear Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Big Bear Bio Inc filed Critical Big Bear Bio Inc
Publication of AU2008260483A1 publication Critical patent/AU2008260483A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AU2008260483A 2007-06-01 2008-05-29 High temperature stable peptide formulation Abandoned AU2008260483A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US94155607P 2007-06-01 2007-06-01
US60/941,556 2007-06-01
US96908007P 2007-08-30 2007-08-30
US60/969,080 2007-08-30
PCT/US2008/006898 WO2008150479A2 (en) 2007-06-01 2008-05-29 High temperature stable peptide formulation

Publications (1)

Publication Number Publication Date
AU2008260483A1 true AU2008260483A1 (en) 2008-12-11

Family

ID=40094334

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008260483A Abandoned AU2008260483A1 (en) 2007-06-01 2008-05-29 High temperature stable peptide formulation

Country Status (7)

Country Link
US (1) US7879805B2 (https=)
EP (1) EP2150537A4 (https=)
JP (1) JP2010530846A (https=)
AU (1) AU2008260483A1 (https=)
CA (1) CA2687246A1 (https=)
MX (1) MX2009012964A (https=)
WO (1) WO2008150479A2 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2952522B1 (en) 2007-01-31 2019-10-30 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
AU2008232709C1 (en) 2007-03-28 2015-01-15 President And Fellows Of Harvard College Stitched polypeptides
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
WO2010062896A1 (en) * 2008-11-28 2010-06-03 Abbott Laboratories Stable antibody compositions and methods for stabilizing same
MX2011011772A (es) * 2009-05-04 2012-02-08 Abbott Biotech Ltd Formulaicones estables de anticuerpos humanos anti-tnf-alfa con alta concentracion de proteina.
SG10201407724YA (en) * 2009-11-23 2014-12-30 Cubist Pharm Inc Daptomycin compositions and related methods
HUE026885T2 (en) 2010-03-31 2016-08-29 Stabilitech Ltd Stabilize virus fragments
EP2552410B1 (en) * 2010-03-31 2018-10-24 Stabilitech Biopharma Ltd Method for preserving alum adjuvants and alum-adjuvanted vaccines
BR112012025047A2 (pt) 2010-03-31 2016-06-21 Stabilitech Ltd formulações líquidas estabilizadas
KR20170058446A (ko) 2010-08-13 2017-05-26 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
SG190069A1 (en) 2010-11-11 2013-06-28 Abbvie Biotechnology Ltd IMPROVED HIGH CONCENTRATION ANTI-TNFa ANTIBODY LIQUID FORMULATIONS
CN102488889B (zh) * 2011-09-26 2014-01-22 上海天伟生物制药有限公司 一种低杂质含量的卡泊芬净制剂及其制备方法和用途
CN103315969B (zh) * 2011-09-26 2016-05-18 上海天伟生物制药有限公司 一种低杂质含量的卡泊芬净制剂及其制备方法和用途
GB201117233D0 (en) 2011-10-05 2011-11-16 Stabilitech Ltd Stabilisation of polypeptides
AR088392A1 (es) 2011-10-18 2014-05-28 Aileron Therapeutics Inc Macrociclos peptidomimeticos
WO2013066795A1 (en) * 2011-11-02 2013-05-10 The University Of Chicago Stable pharmaceutical formulations of growth factor peptides
CA2862038C (en) 2012-02-15 2021-05-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
HK1205454A1 (en) 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
SG11201405578TA (en) * 2012-03-09 2014-11-27 Oncotherapy Science Inc Pharmaceutical composition containing peptide
JP6148487B2 (ja) * 2012-05-31 2017-06-14 久保木　芳徳 チタン−タンパク質複合体の製造方法
EP2698162A1 (en) * 2012-08-15 2014-02-19 Credentis AG Method for producing a composition for treating a tooth lesion
BR112015009470A2 (pt) 2012-11-01 2019-12-17 Aileron Therapeutics Inc aminoácidos dissubstituídos e seus métodos de preparação e uso
US10251935B2 (en) 2012-11-28 2019-04-09 Nono Inc. Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose
GB201406569D0 (en) 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
WO2015181756A1 (en) 2014-05-28 2015-12-03 Nono Inc. Chloride salt of tat-nr2b9c
SG11201702175YA (en) * 2014-09-24 2017-04-27 Aileron Therapeutics Inc Peptidomimetic macrocycles and formulations thereof
WO2016049359A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
US10253067B2 (en) 2015-03-20 2019-04-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
JP2018528217A (ja) 2015-09-10 2018-09-27 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Ｍｃｌ−１のモジュレーターとしてのペプチド模倣大環状分子
GB2562241B (en) 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions
CN109528761A (zh) * 2018-12-20 2019-03-29 江西润泽药业有限公司 制备钠钾钙镁葡萄糖注射液的方法
AU2021233893A1 (en) 2020-03-12 2022-08-25 Baxter Healthcare Sa Daptomycin formulations containing a combination of sorbitol and mannitol
WO2021202577A1 (en) * 2020-03-31 2021-10-07 3-D Matrix, Ltd. Sterilization of self-assembling peptides by irradiation
KR102869156B1 (ko) * 2021-03-29 2025-10-15 (주)아모레퍼시픽 콜라겐 펩티드 안정화용 조성물 및 이를 포함하는 식품

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372716B1 (en) * 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5770700A (en) * 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
AUPO871997A0 (en) * 1997-08-25 1997-09-18 Csl Limited Dried biologically or therapeutically active preparations
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
US6689353B1 (en) * 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2
JP2003055257A (ja) * 2001-08-10 2003-02-26 Nihon Pharmaceutical Co Ltd 安定な血液凝固第ｘｉｉｉ因子製剤
CA2473182A1 (en) * 2002-02-08 2003-08-14 Acologix, Inc. Compositions and methods for treatment of vitamin d deficiency
US20040105778A1 (en) * 2002-10-04 2004-06-03 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
US20060008415A1 (en) * 2004-06-25 2006-01-12 Protein Design Labs, Inc. Stable liquid and lyophilized formulation of proteins
PT1778723E (pt) * 2004-08-17 2013-01-25 Regeneron Pharma Formulações de antagonista de il-1

Also Published As

Publication number Publication date
WO2008150479A3 (en) 2009-02-19
EP2150537A2 (en) 2010-02-10
CA2687246A1 (en) 2008-12-11
US7879805B2 (en) 2011-02-01
EP2150537A4 (en) 2010-09-22
US20090054331A1 (en) 2009-02-26
WO2008150479A2 (en) 2008-12-11
JP2010530846A (ja) 2010-09-16
MX2009012964A (es) 2010-01-14

Similar Documents

Publication Publication Date Title
US7879805B2 (en) High temperature stable peptide formulation
RU2236250C2 (ru) Фармацевтическая композиция, содержащая гормон роста, аминокислоту и неионогенный детергент
US11633462B2 (en) Pharmaceutical composition comprising plasminogen and uses thereof
TWI725973B (zh) 抗-ｃｇｒｐ抗體調配物
CN100475267C (zh) 含甘氨酸的高浓度人生长激素液体制剂
TWI243057B (en) Formulations for protection of peg-interferon alpha conjugates
CA2792965A1 (en) Stable aqueous mia/cd-rap formulations
US20230414698A1 (en) Collagen 7 compositions and methods of using the same
JP2003504346A (ja) 成長ホルモン製剤
JPH10507181A (ja) 成長ホルモンおよびバリンを含んでなる医薬製剤
CA3011609C (en) A lyophilised pharmaceutical formulation and its use
ES2288018T3 (es) Formulaciones inyectables de igf que contienen succinato como tampon.
JP5070670B2 (ja) Ｎ−［ｏ−（ｐ−ピバロイルオキシベンゼンスルホニルアミノ）ベンゾイル］グリシン・モノナトリウム塩・４水和物の凍結乾燥製剤およびその製造方法
JP4880845B2 (ja) Ｇｒｆ含有凍結乾燥薬剤組成物
AU2018328532A1 (en) Pharmaceutical composition of docetaxel conjugate and preparation method
ES2449044T3 (es) Procedimiento de administración de fVIII sin dominio B porcino
AU2005200879B2 (en) GRF-containing lyophilized pharmaceutical compositions
WO2024133908A1 (en) Stable pharmaceutical compositions comprising romiplostim
JP2023553106A (ja) 改善された凍結乾燥製剤
WO2022161554A1 (es) Composición farmacéutica que comprende el ghrp-6
BR112017012972B1 (pt) Composição farmacêutica que compreende plasminogênio e seus usos

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period